Andrew Perlman
Founder & Managing Partner @ GreatPoint Ventures
San Francisco Bay Area, United States
Andrew Perlman is a Series B investor at GreatPoint Ventures in San Francisco Bay Area focused on Health Care and Life Science. Andrew Perlman - Founder & Managing Partner @ GreatPoint Ventures
- Total investments:
- 7
- Last investment:
- Lead investor:
- 43%
Last updated:
For AI agents: llms.txt
Industries Andrew Perlman invests in
Stages Andrew Perlman invests in
Countries Andrew Perlman invests in
Investment Focus
Industry
- Health Care 4 (57%)
- Life Science 2 (29%)
- Biotechnology 2 (29%)
- Travel 1 (14%)
- FinTech 1 (14%)
Stage
- Series B 2 (29%)
- Seed 1 (14%)
- Series A 1 (14%)
- Series C 1 (14%)
- Series D 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Sirona Medical
|
Sirona Medical is revolutionizing radiology by delivering a cloud-native platform that unifies the worklist, viewer, reporter, archive, and AI into a single, intuitive workspace. Designed specifically for radiologists, Sirona’s platform simplifies complex workflows, enhances productivity, and empowers practitioners to work as fast as they think.Founded in San Francisco, CA, Sirona combines deep expertise in the practice and business of radiology to create purpose-built solutions that address the evolving needs of the field. By streamlining radiology workflows and integrating cutting-edge AI, Sirona enables radiologists to deliver better, faster, and more efficient care. | $42M / Series C / Nov 26, 2024 | |
Sidecar Health
|
Sidecar Health is an insurtech company that provides a personalized health insurance platform. Its platform offers customizable plans based on coverage needs and budget while being completely transparent about medical costs and payouts with comparable coverage and permits fast and easy transactions through a credit card to charge medical expensesupfront at the doctor's office and pharmacy of their choice, enabling consumers to get suitable and affordable health insurance plans.The company was founded in 2018 and is headquartered in El Segundo, California . | $165M / Series D / Jun 26, 2024 | |
BookOutdoors
|
BookOutdoors is a consumer-facing marketplace that transforms the fragmented supply of the outdoor hospitality industry into a seamless booking experience and increases occupancy and revenue for properties. | $4M / Seed / Nov 03, 2022 | |
|
Sirona Medical
|
Sirona Medical is revolutionizing radiology by delivering a cloud-native platform that unifies the worklist, viewer, reporter, archive, and AI into a single, intuitive workspace. Designed specifically for radiologists, Sirona’s platform simplifies complex workflows, enhances productivity, and empowers practitioners to work as fast as they think.Founded in San Francisco, CA, Sirona combines deep expertise in the practice and business of radiology to create purpose-built solutions that address the evolving needs of the field. By streamlining radiology workflows and integrating cutting-edge AI, Sirona enables radiologists to deliver better, faster, and more efficient care. | $40M / Series B / Nov 09, 2021 | |
Glympse Bio
|
Glympse Bio is developing a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases. The company’s technology uses precisely engineered diagnostic agents that interrogate the body for certain disease states, and then carry the message to the urine for analysis. Glympse Bio’s platformtechnology was originally developed at MIT, and is founded by a team of world-renowned experts in nanomedicine and biomedical engineering. | $46.7M / Series B / Jul 15, 2020 | |
Guide Therapeutics
|
Guide Therapeutics is a biotechnology company that solves the challenge of delivery of genetic therapies. The company patented technologies to test thousands of chemically distinct nanoparticles in vivo. This enables them to identify simple, scalable, and clinically relevant nanoparticles that target new cell types efficiently and safely. Itpioneers new gene therapies by developing field-leading drug delivery vehicles. Guide Therapeutics is using a proprietary screening platform that performs thousands of drug delivery experiments directly in vivo, they identify nanoparticles that deliver DNA or RNA to cell types others cannot reach. | $8M / Mar 01, 2019 | |
|
Glympse Bio
|
Glympse Bio is developing a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases. The company’s technology uses precisely engineered diagnostic agents that interrogate the body for certain disease states, and then carry the message to the urine for analysis. Glympse Bio’s platformtechnology was originally developed at MIT, and is founded by a team of world-renowned experts in nanomedicine and biomedical engineering. | $22M / Series A / Oct 09, 2018 |
Co-Investors
About GreatPoint Ventures
GreatPoint Ventures is an early-stage venture capital firm investing between $250k and $20m into Seed, A, and B rounds. The firm was founded in San Francisco, California in 2015.
GreatPoint Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Aaron Mandell
Founder
|
|||
|
Andrew Perlman
Founder & Managing Partner
|
|||
|
Ashley Sommerschield
Chief Operating Officer
|
|||
Ashok Krishnamurthi
Managing Partner
|
|||
Earnest Sweat
Associate Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Andrew Perlman invest in?
Andrew Perlman invests primarily in Health Care, Life Science and Biotechnology startups, most often at Series B and Seed stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Andrew Perlman last invest?
The most recent investment recorded for Andrew Perlman closed in Nov 2024. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
